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GENERATION OF A TRANSGENIC KNOCK-IN MOUSE MODEL
EXPRESSING ONLY THE IIA ISOFORM OF TYPE II PROCOLLAGEN
S. Ravindran1, R. Lewis1, R.J. Fernandes2, A. McAlinden1. 1Washington
Univ., St Louis, MO, USA; 2Univ. of Washington, Seattle, WA, USA
Purpose: To generate a mouse model where alternative pre-mRNA
splicing of the type II procollagen gene (COL2A1) is inhibited. Normally,
chondroprogenitor cells synthesize predominantly exon 2-containing
mRNA isoforms of COL2A1 (type IIA and IID) while differentiated
chondrocytes mainly generate COL2A1 mRNA isoforms devoid of exon
2 (type IIB). The biological signiﬁcance of this splicing switch with
respect to cartilage/skeletal development and maintenance is not known.
To address this issue, we synthesized a transgenic mouse expressing
predominantly the IIA isoform of COL2A1 by altering the 5′ splice site
sequence of exon 2.
Methods: A 4ntd mutation was created at the 5′ splice site of exon 2 in a
COL2A1 mini-gene construct. This mutation converts exon 2 from a weak
splice site to strong consensus splice site. Wild type and mutant mini-
genes were transfected into chondrocyte cell lines and spliced isoforms
were analyzed by RT-PCR. To generate the mouse model, a targeting
vector was made containing one short arm (~2kB) and one long arm
(~7kb including the 4ntd splice site mutation) of the Col2a1 locus.
Targeting vector was electroporated into ES cells (129S6/SvEvTac) and
Southern blotting identiﬁed homologously-recombined clones. Positive
ES clones were injected into C57BL/6 blastocysts to generate chimeric
mice. Further breedings were done to generate heterozygote mice devoid
of the neomycin cassette by crossing to Cre-expressing mice (EIIa-Cre).
Resulting heterozygote mice were bred to generate WT, +/− and −/− mice
for analyses. Epiphyseal cartilage was dissected from limbs of P7, P14
and P28 litters and RT-PCR was carried out to detect the ratio of IIA / IID
and IIB mRNA. Parafﬁn tissue sections of hindlimbs were analyzed by
Safranin-O staining or immunohistochemistry using antibodies against
the triple-helical domain or the exon2-encoded domain of type II
procollagen. 4M guanidine extracts from epiphyseal cartilage tissue were
analyzed by Western blotting using the same type II procollagen Abs.
Results: Splicing of the mutant COL2A1 mini-gene by cells in vitro
resulted in synthesis of predominantly the IIA isoform. Homologous
recombination of the targeting vector in vivo resulted in positive ES
clones. Chimeric mice were generated following blastocyst injections of
ES clones and germline transmission was conﬁrmed by PCR. Homozygote
mice were generated at the expected Mendelian ratio. No overt
phenotype was noted in the +/− and −/− mice compared to WT
littermates. RT-PCR conﬁrmed that IIA is the predominant isoform
produced in epiphyseal cartilage from homozygote mice while WT
mice produced mainly IIB mRNA at all three time points (P7, P14,
P28) as expected. Immunohistochemistry showed a dramatic increase
in localization of the IIA propeptide in proximal tibial cartilage of +/−
and −/− mice when compared to WT. Western blotting showed that
procollagen processing occurs in the matrix of +/− and −/− mice at P7
although levels of unprocessed proa1 (IIA) and pN-a1(IIA) were also
identiﬁed.
Conclusions: Global knock-in mice have been generated that express
predominantly the IIA isoform of type II procollagen by altering a
4ntd sequence of the 5′ splice site of exon 2. Preliminary histological
analyses suggest that cartilage development is normal even though
there is persistent and high expression of IIA propeptide protein in
the matrix at post-natal time points when this protein is not normally
present. Future studies will involve analyzing whether other cartilage
matrix components have been altered as a result of changing type II
collagen isoform expression. Investigation of cartilage maintenance over
time with normal ageing or as a result of osteoarthritis induction (DMM
model) will also be carried out.
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GREATER TROCHANTERIC PAIN IN HIP OSTEOARTHRITIS: INFLUENCE
ON SYMPTOM SEVERITY
A. Brinks, R. Rozendaal, B.W. Koes, J.A. Verhaar, S.M. Bierma-Zeinstra.
Erasmus MC, Univ. Med. Ctr., Rotterdam, Netherlands
Purpose: Patients with hip osteoarthritis (OA) often show a pattern with
periods of increased pain (ﬂares). Little is known about the association
between the co-existence of a tendinitis of the gluteus medius muscle or
a trochanteric bursitis, known as greater trochanteric pain syndrome
(GTPS), and these ﬂuctuations in pain. In this study we assess the
frequency of GTPS in hip OA patients, the association with symptom
severity in hip OA, and the association of ﬂuctuation in presence of GTPS
and ﬂuctuations in symptom severity.
Methods: We used data from baseline and 24-months assessments of
a RCT in which primary care hip OA patients meeting the ACR criteria
were randomly assigned to receive either glucosamine sulfate or placebo.
Symptom severity (0–100) was assessed with WOMAC scores for pain,
function and stiffness and with a visual analogue scale (VAS) for pain in
the past week. GTPS was deﬁned as tenderness at the greater trochanter
in combination with pain recognition, and with a painful resisted hip
abduction. We used linear regression models to analyze the adjusted
inﬂuence of GTPS on the symptom severity in hip OA patients. We also
assessed the prognostic value of GTPS on symptom severity 24 months
later, and whether individual changes in severity scores associated with
changes in presence of GTPS between the two time points.
Results: Of the 214 hip OA patients, 36 patients (17%) showed GTPS
at baseline. Using adjusted regression models, the hip OA patients
with GTPS at baseline showed a statistically signiﬁcant higher mean
WOMAC pain and stiffness severity (8.1 and 6.9 points respectively) and
higher VAS pain severity (12.8 points). GTPS at baseline did not predict
symptom severity 24 months later, but GTPS at 24 months follow-up
was statistically signiﬁcant associated with higher symptom scores at
24 months (13.1, 10.6 and 18.0 points respectively for WOMAC pain,
function, and stiffness, and of 12.1 points for VAS pain). Change in
presence of GTPS associated with ﬂuctuations in symptom severity with
13.1, 9.4 and 11 points for the WOMAC scores respectively, and with 15.6
points for the VAS-score.
Conclusions: Primary care hip OA patients have in one of ﬁve co-existent
GTPS, which associates with higher symptom scores.
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ASSOCIATIONS BETWEEN INFLAMMATORY BIOMARKERS AND
CHANGE IN KNEE PAIN OVER 5 YEARS IN OLDER ADULTS
C. Ding1,2, O. Stannus1, L. Blizzard1, G. Jones1. 1Univ. of Tasmania, Hobart,
Australia; 2Monash Univ., Melbourne, Australia
Purpose:While increasing evidence supports the idea of inﬂammation in
osteoarthritis (OA) pathogenesis, whether these inﬂammatory markers
are predictive of knee pain is unknown. We investigated if both baseline
and change over 2.6 years in serum levels of tumor necrosis factor
(TNF)-a, interleukin (IL)-6 and high-sensitivity C-reactive protein (hs-
CRP) were associated with change in pain over 5 years.
Methods: A total of 149 randomly selected subjects (mean 63 years, range
52–78; 46% female) were studied. Serum samples were taken at baseline
and 2.6 years later. TNF-a, IL-6 and hs-CRP levels were measured by
radioimmunoassay. Knee pain was recorded using the Western Ontario
and McMasters Osteoarthritis Index (WOMAC) questionnaire at baseline
and 5 years later. Knee radiographic osteoarthritis (ROA) of both knees
was assessed at baseline.
Results: After adjustment for confounding variables, both baseline
(b=0.27mL/pg, p = 0.029) and change per annum (b=.91mL/pg, p = 0.010)
in TNF-a were positively associated with change in total knee pain.
In addition, baseline and change in TNF-a was signiﬁcantly positively
associated with change in the standing and/or on stairs sub-scale of
knee pain. Baseline IL-6 levels were positively associated with change
in the standing sub-scale of pain (b=0.18mL/pg, p = 0.046), but change
per annum in IL-6 was negatively associated with change in the sub-
scale of pain lying in bed (b = −0.56mL/pg, p = 0.023). Baseline hs-CRP
was positively associated with change in total knee pain (b=0.38/pg,
p = 0.048), as well as change in the sub-scales for pain while lying in bed
(b=0.14mL/pg, p = 0.019) and sitting (b=0.13mL/pg, p = 0.004).
Conclusions: While TNF-a and hs-CRP are predictive of increased knee
pain, IL-6 is inconsistently associated with increases in knee pain over
time. The underlying mechanisms need to be explored.
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THE COURSE OF PAIN IN HIP OSTEOARTHRITIS; DEFINING
TRAJECTORIES OVER A TWO YEARS TIME PERIOD
S.P. Verkleij1, T. Hoekstra2, P.A. Luijsterburg1, E. Waarsing1, B.W. Koes1,
S.M. Bierma-Zeinstra1. 1Erasmus MC, Rotterdam, Netherlands; 2VU Univ.,
Amsterdam, Netherlands
Purpose: Osteoarthritis (OA) is the most frequent chronic joint disease of
the elderly, causing pain and disability. On average, pain due to OA seems
